Imunon (NASDAQ:IMNN) Receives Buy Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of Imunon (NASDAQ:IMNN) in a report published on Monday,Benzinga reports. They currently have a $29.00 price objective on the stock.

Other equities research analysts also recently issued research reports about the stock. HC Wainwright lowered their target price on shares of Imunon from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Monday, November 11th. EF Hutton Acquisition Co. I raised shares of Imunon to a “strong-buy” rating in a research note on Monday, September 23rd.

Imunon Price Performance

IMNN opened at $0.81 on Monday. Imunon has a fifty-two week low of $0.48 and a fifty-two week high of $3.65. The company has a market cap of $11.79 million, a price-to-earnings ratio of -0.43 and a beta of 2.14. The firm has a 50 day simple moving average of $0.94 and a 200 day simple moving average of $1.15.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.